Bill Text: NY A04276 | 2017-2018 | General Assembly | Introduced
Bill Title: Amends the dosing limitations and medical conditions permitting the use of medical marihuana.
Spectrum: Partisan Bill (Democrat 35-1)
Status: (Introduced - Dead) 2018-05-14 - starred on calendar [A04276 Detail]
Download: New_York-2017-A04276-Introduced.html
STATE OF NEW YORK ________________________________________________________________________ 4276 2017-2018 Regular Sessions IN ASSEMBLY February 2, 2017 ___________ Introduced by M. of A. GOTTFRIED, LUPARDO, DINOWITZ, PAULIN, HEVESI, BLAKE, BRINDISI, COOK, ORTIZ, JENNE, SEPULVEDA, SIMON, SKARTADOS, SKOUFIS, ZEBROWSKI, McDONALD -- read once and referred to the Commit- tee on Health AN ACT to amend the public health law, in relation to dosing limitations and medical conditions permitting the medical use of marihuana The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Subdivision 15 of section 3360 of the public health law, as 2 added by chapter 90 of the laws of 2014, is amended to read as follows: 3 15. "Individual dose" means a single measure of raw medical marihuana 4 or non-infused concentrates to be determined and clearly identified by a 5 patient's practitioner for the patient's specific certified condition. 6 [For ingestible or sub-lingual medical marihuana products, no individual7dose may contain more than ten milligrams of tetrahydrocannabinol.] 8 § 2. Subdivision 7 of section 3360 of the public health law, as added 9 by chapter 90 of the laws of 2014, is amended to read as follows: 10 7. [(a)] "Serious condition" means: 11 (i) having one of the following severe debilitating or life-threaten- 12 ing conditions: cancer, positive status for human immunodeficiency virus 13 or acquired immune deficiency syndrome, amyotrophic lateral sclerosis, 14 Alzheimer's disease, traumatic brain injury, dystonia, Parkinson's 15 disease, multiple sclerosis, muscular dystrophy, damage to the nervous 16 tissue of the spinal cord with objective neurological indication of 17 intractable spasticity, epilepsy, wasting syndrome, post traumatic 18 stress disorder, rheumatoid arthritis, lupus, inflammatory bowel 19 disease, neuropathies, Huntington's disease, or as added by the commis- 20 sioner; [and] or 21 (ii) any of the following conditions where it is clinically associated 22 with, or a complication of, a condition under this paragraph or its 23 treatment: cachexia or wasting syndrome; severe or chronic pain; severe EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD02522-01-7A. 4276 2 1 nausea; seizures; severe or persistent muscle spasms; or such conditions 2 as are added by the commissioner. 3 [(b) No later than eighteen months from the effective date of this4section, the commissioner shall determine whether to add the following5serious conditions: Alzheimer's, muscular dystrophy, dystonia, post-6traumatic stress disorder and rheumatoid arthritis.] 7 § 3. This act shall take effect immediately; provided that the amend- 8 ments to title 5-a of article 33 of the public health law made by this 9 act shall not affect the repeal of such title and shall be deemed 10 repealed therewith.